L3VLUP
ProSign in

TEVA · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TEVAVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TEVA
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterTEVAVRTX
Q3 20207 holders, $2.1bn31 holders, $21.9bn
Q4 20205 holders, $2.2bn30 holders, $18.4bn
Q1 20218 holders, $2.6bn31 holders, $15.4bn
Q2 20217 holders, $2.1bn30 holders, $12.7bn
Q3 20216 holders, $1.7bn35 holders, $10.1bn
Q4 20214 holders, $1.1bn28 holders, $12.4bn
Q1 20229 holders, $1.4bn23 holders, $16.1bn
Q2 202211 holders, $913m25 holders, $18.1bn
Q3 202211 holders, $1.4bn22 holders, $18.4bn
Q4 202211 holders, $1.7bn28 holders, $18.4bn
Q1 20238 holders, $1.3bn26 holders, $21.4bn
Q2 202310 holders, $184m27 holders, $24.7bn
Q3 202313 holders, $384m33 holders, $24.3bn
Q4 202310 holders, $373m32 holders, $28.6bn
Q1 202416 holders, $666m31 holders, $29.8bn
Q2 202422 holders, $1.8bn29 holders, $33.4bn
Q3 202422 holders, $2.3bn27 holders, $33.5bn
Q4 202418 holders, $3.0bn26 holders, $28.5bn
Q1 202512 holders, $2.0bn21 holders, $35.4bn
Q2 202511 holders, $1.8bn21 holders, $32.3bn
Q3 202514 holders, $964m22 holders, $25.9bn
Q4 202516 holders, $2.1bn26 holders, $31.8bn
Q1 202614 holders, $2.0bn25 holders, $31.8bn
Q2 202614 holders, $2.4bn26 holders, $34.6bn
TEVA

Teva Pharmaceutical Inds LTD

Holders
14
Reported value
$2.4bn
Buyers
18
Sellers
16

Breadth +2 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TEVA (6)

ARK Investment Management LLC, Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Greenlight Capital

Only VRTX (18)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Citadel Advisors LLC, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →